Kalgene’s Series A marks start of Lumira Capital’s next chapter
This year has been eventful for Lumira Capital. The Toronto life-sciences investor held a first close for Fund IV, completed the fund’s debut deals, tied up investing by prior funds, and took a portfolio star public. One milestone was met in this week's announcement of the Series A financing of Kalgene Pharmaceuticals, a developer of treatments for Alzheimer’s disease. Lumira led the undisclosed round and was joined by Anges Québec, Anges Québec Capital, Accel-Rx and family offices. Kalgene is the final deal of Merck Lumira Biosciences Fund, an early-stage vehicle managed by Lumira, which together with the later-stage Lumira Capital II raised $167 million over 2012-2013. With both funds now fully invested, Lumira is positioned to bring Lumira Capital IV to a final close in 2018 and back a new series of North American biotech financings.
